Cory Renauer
Value, research analyst, biotech, small-cap

Isis Pharmaceuticals Making Antisense

Building roadblocks between transcription and translation

Isis Pharmaceuticals (ISIS) pioneers a drug development platform that targets specific mRNA strands, after transcription, and stops them from being translated into troublesome proteins. Despite its unfortunate name, antisense technology is an extremely good method for creating the sort of highly targeted compounds the FDA likes.

Through antisense based drug development, Isis has become a highly efficient drug discovery machine. It is so efficient that Isis couldn't possibly afford to test and market even a fraction of the compounds it creates, so it doesn't

In a nutshell, Isis's business model consists of it discovering and developing drugs, then letting the grown-ups do the dirty work. Isis has licensing agreements with AstraZeneca (NYSE:...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details